Company profile

Hanmi Pharmaceutical

128940 · KRX · South Korea

Public Market Listing

128940KRX

KRX primary exchange listing

Live quotes, historical charts, and market capitalization for Hanmi Pharmaceutical are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(4 total)
4Total Assets
0Approved
1Phase 3 / Filed
3Phase 1–2 / Early
3Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
efpeglenatide
Phase 3
GLP-1 receptorPeptide
Type 2 Diabetes
HM15275
Phase 2
GLP-1/GIP/glucagon receptor (triple)Peptide
Obesity
Tuspetinib
Phase 2
FLT3 (wild-type and mutant, including ITD/TKD), SYKSmall molecule
Acute Myeloid Leukemia
HM15211No recent activity
Phase 1
GLP-1/GIP/glucagon receptor (triple)Peptide
Obesity

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.